Now Available: Spotlight on Stilla Technologies Remi Dangla, PhD – CEO. Click here to read.
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today it has extended its Series A financing round with an additional close of $25.5 million, bringing the total Series A amount raised to $59.5 million.
Precede Biosciences emerges from stealth today with a breakthrough, comprehensive, blood-based approach to revealing disease-defining transcriptional biology – a first for the diagnostic field.
Iambic’s unique AI-Driven drug-discovery platform identifies potential first-in-class and best-in-class development candidates years faster than industry norms. Funding will support continued AI platform innovations and advancement of multiple candidates into clinical development, Including IAM-H1, a selective brain-penetrant HER2 Inhibitor, and IAM-C1, a selective dual CDK2/4 inhibitor.
Illumina Ventures today announced that Mara Aspinall, MBA, has joined the Company’s investment team as a Partner.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
